Despite their advantages, combination products present new technological and organizational challenges. They require new product development strategies compared to standalone products, drugs, and devices.
Wicked problems – chronic health issues such as diabetes, obesity, and endocrine disorders – are projected to affect close to one billion people worldwide by 2045. By planning ahead and investing in digital healthcare solutions for connected drug delivery, companies such as Novo Nordisk are aiming to meet rising demands for the provision of healthcare as they occur.
In this commentary article, we present Axel Becker's insights on the latest techniques governing API particle properties and the processes that dictate the success of drug reception and tablet compression.
This month, the discussion group debated the advantages and disadvantages of different types of inhalers. One key area of interest was current-day challenges with aerosol delivery, which could be addressed through smart inhalers and other innovative new devices.
The pharmaceutical industry has historically taken a cautious approach to most new advancements, but now it is embracing the possibilities of continuous manufacturing technologies. While traditional batch-based processes are still more common, there are several products on the market that have utilized continuous manufacturing practices.
RNA based therapeutics, particularly mRNA, has been experiencing a period of rapid growth, partly due to the influx of funding for mRNA Covid-19 Vaccines. One area that has the potential to benefit from mRNA vaccines is cancer. There are various techniques that have potential to combat the deadly disease.
This November, our Formulation Series discussion group focused on the formulation and delivery of inhaled biologics. Oxford Global’s discussion groups bring together a select group of 15-20 key industry leaders for approximately one hour for in depth knowledge sharing and conversation.
This September, our formulation series discussion group focused on the delivery of oral biologics. Biologic-based therapies have soared in popularity and now account for approximately 12% of the pharmaceutical market.
We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.